The clinical application of
doxorubicin (Dox) is limited by its adverse effect of
cardiotoxicity. Previous studies have suggested the cardioprotective effect of
brain-derived neurotrophic factor (
BDNF). We hypothesize that
BDNF could protect against Dox-induced
cardiotoxicity. Sprague Dawley rats were injected with Dox (2.5 mg/kg, 3 times/week, i.p.), in the presence or absence of recombinant
BDNF (0.4 μg/kg, i.v.) for 2 weeks. H9c2 cells were treated with Dox (1 μM) and/or
BDNF (400 ng/ml) for 24 hrs. Functional roles of
BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro.
Protein level of
BDNF was reduced in Dox-treated rat ventricles, whereas
BDNF and its receptor
tropomyosin-related
kinase B (TrkB) were markedly up-regulated after
BDNF administration.
Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats. Meanwhile,
BDNF increased cell viability, inhibited apoptosis and DNA damage of Dox-treated H9c2 cells. Investigations of the underlying mechanisms revealed that
BDNF activated Akt and preserved phosphorylation of
mammalian target of rapamycin and Bad without affecting
p38 mitogen-activated protein kinase and extracellular regulated
protein kinase pathways. Furthermore, the beneficial effect of
BDNF was abolished by
BDNF scavenger TrkB-Fc or Akt inhibitor. In conclusion, our findings reveal a potent protective role of
BDNF against Dox-induced
cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in
cancer treatment.